Technology Bundle ID: TAB-2601

Use of Vitronectin as a Biomarker for the Detection of Dengue Hemorrhagic Fever

Request More Info
Licensing Contact:
Primary Inventors: 
Elizabeth Hunsperger (CDC)
Betty Poole-Smith (CDC), Kay Tomashek (CDC), Momar Ndao (McGill University)
Development Status: 
  • Pre-clinical
  • In vitro data available
Institute or Center: 

Dengue hemorrhagic fever (DHF) is a severe, potentially deadly infection spread by mosquitos. CDC scientists have identified vitronectin as an important biomarker of DHF. They have shown vitronectin is significantly reduced in DHF and severe dengue infections when compared to dengue non-hemorrhagic fever patients. Presently, DHF is established by assessing antibody concentrations and other rule-of-thumb criteria, but often these assays can be difficult to interpret and lead to false conclusions. Establishing vitronectin levels provides a specific, novel biomarker for DHF, leading to increased accuracy in clinical diagnoses and improved patient outcomes.

  • Diagnostic biomarker of DHF
  • Point-of-care diagnostic testing
  • Enzyme-linked immunosorbent assay (ELISA) for clinical and laboratory use
  • While there are commercially-available ELISAs to detect vitronectin, these products have not been used for dengue diagnosis
  • Vitronectin assessment assays provide a novel, specific biomarker for the DHF disease state
  • Easily developed for serologic diagnostic assays


PCT Application PCT/US12/025472
Filed on 2012-02-16
US Application 13/985,507
Filed on 2015-05-07
US Application 61/443,554
Filed on 2011-02-16


Poole-Smith BK, et al. Discovery and Validation of Prognostic Biomarkers for Severe Dengue by Proteomic Screening. International Conference on Emerging Infectious Diseases 2012: poster and oral presentation abstracts. Emerg Infect Dis. 2012 Mar.


Aug 2, 2013

Data Source: